D

espite the outcomes of both the presidential election and the Brexit vote, this could be a banner year for biopharma mergers and acquisitions, according to two new reports.

Biopharma valuations leveled off substantially in 2016, which sets the stage this year for several new divestitures and megadeals, according to a new report from consulting firm EY.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X